120,562 Shares in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Acquired by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC acquired a new position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 120,562 shares of the biopharmaceutical company’s stock, valued at approximately $760,000. TIAA CREF Investment Management LLC owned about 0.24% of Corbus Pharmaceuticals Holdings at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in CRBP. Bank of New York Mellon Corp grew its stake in shares of Corbus Pharmaceuticals Holdings by 7.7% in the 1st quarter. Bank of New York Mellon Corp now owns 21,102 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 1,511 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Corbus Pharmaceuticals Holdings by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock worth $10,357,000 after acquiring an additional 71,419 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Corbus Pharmaceuticals Holdings by 16.5% in the first quarter. Geode Capital Management LLC now owns 201,177 shares of the biopharmaceutical company’s stock worth $1,659,000 after acquiring an additional 28,492 shares in the last quarter. Credit Suisse AG purchased a new position in shares of Corbus Pharmaceuticals Holdings in the first quarter worth approximately $157,000. Finally, Creative Planning increased its position in shares of Corbus Pharmaceuticals Holdings by 3.9% in the second quarter. Creative Planning now owns 173,475 shares of the biopharmaceutical company’s stock worth $1,093,000 after acquiring an additional 6,525 shares in the last quarter. 29.20% of the stock is currently owned by institutional investors.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) opened at $6.85 on Tuesday. Corbus Pharmaceuticals Holdings, Inc. has a 1 year low of $5.30 and a 1 year high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The firm had revenue of $0.80 million for the quarter. sell-side analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on CRBP shares. Noble Financial lifted their target price on shares of Corbus Pharmaceuticals Holdings from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. ValuEngine downgraded shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Cantor Fitzgerald set a $24.00 target price on shares of Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $20.75.

ILLEGAL ACTIVITY WARNING: “120,562 Shares in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Acquired by TIAA CREF Investment Management LLC” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.truebluetribune.com/2017/11/14/120562-shares-in-corbus-pharmaceuticals-holdings-inc-crbp-acquired-by-tiaa-cref-investment-management-llc.html.

In related news, Director David P. Hochman acquired 10,000 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average cost of $7.08 per share, with a total value of $70,800.00. Following the completion of the transaction, the director now owns 459,500 shares of the company’s stock, valued at approximately $3,253,260. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased 15,336 shares of company stock worth $108,382 over the last ninety days. 11.90% of the stock is currently owned by insiders.

Corbus Pharmaceuticals Holdings Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply